NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it will host a business update call on Wednesday, November 12, at 8:00 a.m. ET to discuss a series of recent clinical, strategic, and financial milestones that mark a pivotal moment for the biomedical innovator.
The call will highlight the company’s expanded collaboration with Medtronic, a new strategic capital relationship with Ligand Pharmaceuticals, and a right of first refusal agreement with Terumo Corporation. Management is also expected to provide updates on the acceleration of patient enrollment in the BACKBEAT pivotal study of its Atrioventricular Interval Modulation (AVIM) Therapy and the launch of enrollment in the Virtue SAB U.S. pivotal IDE coronary trial.
Participants can access the conference call by dialing 877-407-9039 (U.S.) or 201-689-8470 (international), using Conference ID 13756518. A live webcast will also be available at this link.
Orchestra BioMed is a next-generation biomedical innovation company focused on accelerating life-changing technologies through strategic partnerships with leading global medical device manufacturers. Its two flagship candidates—AVIM Therapy and the Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB)—are advancing through pivotal clinical trials targeting multi-billion-dollar market opportunities.
AVIM Therapy, developed in collaboration with Medtronic, is a bioelectronic treatment for hypertension designed to be integrated into pacemaker systems. The therapy aims to deliver immediate and sustained reductions in blood pressure for patients with hypertensive heart disease and has received FDA Breakthrough Device Designation.
Virtue SAB, meanwhile, represents a first-of-its-kind drug-delivery angioplasty balloon engineered to release a proprietary formulation of sirolimus for treating atherosclerotic artery disease. It has also earned FDA Breakthrough Device Designation for several key indications, including coronary small vessel disease and below-the-knee peripheral artery disease.
As Orchestra BioMed advances these high-impact therapies, the company’s upcoming update is expected to outline its next phase of growth and reaffirm its strategic positioning within the global cardiovascular innovation landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.